{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T14:01:23Z","timestamp":1786975283885,"version":"build-2736575974"},"reference-count":52,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1124\/dmd.117.079624","type":"journal-article","created":{"date-parts":[[2018,2,22]],"date-time":"2018-02-22T16:52:58Z","timestamp":1519318378000},"page":"485-492","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["Apixaban and Rosuvas\u00ad\u00adtatin Pharmacokinetics in Nonalcoholic Fatty Liver Disease"],"prefix":"10.1016","volume":"46","author":[{"given":"Rommel G.","family":"Tirona","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahra","family":"Kassam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Strapp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mala","family":"Ramu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ute I.","family":"Schwarz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard B.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bandar","family":"Al-Judaibi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie D.","family":"Beaton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/dmd.117.079624_bib1","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1097\/MPG.0b013e3181f9b3a0","article-title":"Acetaminophen pharmacokinetics in children with nonalcoholic fatty liver disease","volume":"52","author":"Barshop","year":"2011","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1124\/dmd.117.079624_bib2","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.thromres.2016.12.008","article-title":"Changes of in vitro potency of anticoagulant drugs are similar between patients with cirrhosis due to alcohol or non-alcoholic fatty liver disease","volume":"150","author":"Bos","year":"2017","journal-title":"Thromb Res"},{"key":"10.1124\/dmd.117.079624_bib3","doi-asserted-by":"crossref","first-page":"2950","DOI":"10.1210\/jc.2017-00867","article-title":"Liver safety of statins in prediabetes or T2DM and nonalcoholic steatohepatitis: post hoc analysis of a randomized trial","volume":"102","author":"Bril","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1124\/dmd.117.079624_bib4","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1002\/hep.24127","article-title":"Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings","volume":"53","author":"Brunt","year":"2011","journal-title":"Hepatology"},{"key":"10.1124\/dmd.117.079624_bib5","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1124\/dmd.114.062703","article-title":"Altered regulation of hepatic efflux transporters disrupts acetaminophen disposition in pediatric nonalcoholic steatohepatitis","volume":"43","author":"Canet","year":"2015","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.117.079624_bib6","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1053\/j.gastro.2012.04.001","article-title":"The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology","volume":"142","author":"Chalasani","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1124\/dmd.117.079624_bib7","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1148\/radiol.11101942","article-title":"Early detection of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease by using MR elastography","volume":"259","author":"Chen","year":"2011","journal-title":"Radiology"},{"key":"10.1124\/dmd.117.079624_bib8","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1124\/jpet.113.211284","article-title":"Experimental nonalcoholic steatohepatitis increases exposure to simvastatin hydroxy acid by decreasing hepatic organic anion transporting polypeptide expression","volume":"348","author":"Clarke","year":"2014","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.117.079624_bib9","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jhep.2014.02.021","article-title":"Synergistic interaction between genetics and disease on pravastatin disposition","volume":"61","author":"Clarke","year":"2014","journal-title":"J Hepatol"},{"key":"10.1124\/dmd.117.079624_bib10","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1111\/liv.13362","article-title":"Impaired N-linked glycosylation of uptake and efflux transporters in human non-alcoholic fatty liver disease","volume":"37","author":"Clarke","year":"2017","journal-title":"Liver Int"},{"key":"10.1124\/dmd.117.079624_bib11","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1161\/CIRCGENETICS.113.000099","article-title":"Clinical and pharmacogenetic predictors of circulating atorvastatin and rosuvastatin concentrations in routine clinical care","volume":"6","author":"DeGorter","year":"2013","journal-title":"Circ Cardiovasc Genet"},{"key":"10.1124\/dmd.117.079624_bib12","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1002\/hep.29085","article-title":"Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta-analysis","volume":"65","author":"Dulai","year":"2017","journal-title":"Hepatology"},{"key":"10.1124\/dmd.117.079624_bib13","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.jhep.2016.06.005","article-title":"MRI and MRE for non-invasive quantitative assessment of hepatic steatosis and fibrosis in NAFLD and NASH: clinical trials to clinical practice","volume":"65","author":"Dulai","year":"2016","journal-title":"J Hepatol"},{"key":"10.1124\/dmd.117.079624_bib14","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1053\/jhep.2003.50342","article-title":"CYP2E1 activity before and after weight loss in morbidly obese subjects with nonalcoholic fatty liver disease","volume":"38","author":"Emery","year":"2003","journal-title":"Hepatology"},{"key":"10.1124\/dmd.117.079624_bib15","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/S0009-9236(96)90001-6","article-title":"Antipyrine as a probe for human oxidative drug metabolism: identification of the cytochrome P450 enzymes catalyzing 4-hydroxyantipyrine, 3-hydroxymethylantipyrine, and norantipyrine formation","volume":"59","author":"Engel","year":"1996","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.117.079624_bib16","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1002\/cpt.66","article-title":"Altered morphine glucuronide and bile acid disposition in patients with nonalcoholic steatohepatitis","volume":"97","author":"Ferslew","year":"2015","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.117.079624_bib17","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1111\/j.1440-1746.1991.tb00915.x","article-title":"Non-alcoholic steatohepatitis: impaired antipyrine metabolism and hypertriglyceridaemia may be clues to its pathogenesis","volume":"6","author":"Fiatarone","year":"1991","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1124\/dmd.117.079624_bib18","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1111\/bcp.12541","article-title":"Effect of ketoconazole and diltiazem on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor","volume":"79","author":"Frost","year":"2015","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.117.079624_bib19","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1124\/dmd.111.041012","article-title":"Variations in ATP-binding cassette transporter regulation during the progression of human nonalcoholic fatty liver disease","volume":"39","author":"Hardwick","year":"2011","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.117.079624_bib20","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1053\/j.gastro.2006.02.034","article-title":"Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics","volume":"130","author":"Ho","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1124\/dmd.117.079624_bib21","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1194\/jlr.D800017-JLR200","article-title":"Highly sensitive analysis of sterol profiles in human serum by LC-ESI-MS\/MS","volume":"49","author":"Honda","year":"2008","journal-title":"J Lipid Res"},{"key":"10.1124\/dmd.117.079624_bib22","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1124\/dmd.105.007534","article-title":"ATP-dependent transport of rosuvastatin in membrane vesicles expressing breast cancer resistance protein","volume":"34","author":"Huang","year":"2006","journal-title":"Drug Metab Dispos"},{"issue":"8A","key":"10.1124\/dmd.117.079624_bib23","doi-asserted-by":"crossref","first-page":"44C","DOI":"10.1016\/j.amjcard.2005.12.009","article-title":"Statin safety: lessons from new drug applications for marketed statins","volume":"97","author":"Jacobson","year":"2006","journal-title":"Am J Cardiol"},{"key":"10.1124\/dmd.117.079624_bib24","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/clpt.2009.79","article-title":"ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin","volume":"86","author":"Keskitalo","year":"2009","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.117.079624_bib25","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1124\/dmd.108.021410","article-title":"Involvement of multiple transporters in the hepatobiliary transport of rosuvastatin","volume":"36","author":"Kitamura","year":"2008","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.117.079624_bib26","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1161\/CIRCRESAHA.109.203596","article-title":"Human skeletal muscle drug transporters determine local exposure and toxicity of statins","volume":"106","author":"Knauer","year":"2010","journal-title":"Circ Res"},{"key":"10.1124\/dmd.117.079624_bib27","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41540-017-0012-5","article-title":"Translational learning from clinical studies predicts drug pharmacokinetics across patient populations","volume":"3","author":"Krauss","year":"2017","journal-title":"NPJ Syst Biol Appl"},{"key":"10.1124\/dmd.117.079624_bib28","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/S0025-6196(24)00530-5","article-title":"Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease","volume":"55","author":"Ludwig","year":"1980","journal-title":"Mayo Clin Proc"},{"key":"10.1124\/dmd.117.079624_bib29","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1148\/rg.295085186","article-title":"Imaging-based quantification of hepatic fat: methods and clinical applications","volume":"29","author":"Ma","year":"2009","journal-title":"Radiographics"},{"key":"10.1124\/dmd.117.079624_bib30","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s00228-015-1946-4","article-title":"Population pharmacokinetics of rosuvastatin in pediatric patients with heterozygous familial hypercholesterolemia","volume":"72","author":"Macpherson","year":"2016","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1124\/dmd.117.079624_bib31","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1177\/0091270002042012008","article-title":"No effect of rosuvastatin on the pharmacokinetics of digoxin in healthy volunteers","volume":"42","author":"Martin","year":"2002","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/dmd.117.079624_bib32","doi-asserted-by":"crossref","first-page":"2822","DOI":"10.1016\/S0149-2918(03)80336-3","article-title":"Metabolism, excretion, and pharmacokinetics of rosuvastatin in healthy adult male volunteers","volume":"25","author":"Martin","year":"2003","journal-title":"Clin Ther"},{"key":"10.1124\/dmd.117.079624_bib33","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/j.jhep.2014.11.034","article-title":"Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management","volume":"62","author":"McPherson","year":"2015","journal-title":"J Hepatol"},{"key":"10.1124\/dmd.117.079624_bib34","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.hepres.2005.10.001","article-title":"Relationship between in vivo chlorzoxazone hydroxylation, hepatic cytochrome P450 2E1 content and liver injury in obese non-alcoholic fatty liver disease patients","volume":"34","author":"Orellana","year":"2006","journal-title":"Hepatol Res"},{"key":"10.1124\/dmd.117.079624_bib35","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1038\/sj.clpt.6100220","article-title":"Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin","volume":"82","author":"Pasanen","year":"2007","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.117.079624_bib36","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1002\/cpt.525","article-title":"Validation of a microdose probe drug cocktail for clinical drug interaction assessments for drug transporters and CYP3A","volume":"101","author":"Prueksaritanont","year":"2017","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.117.079624_bib37","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1124\/dmd.108.023143","article-title":"Apixaban metabolism and pharmacokinetics after oral administration to humans","volume":"37","author":"Raghavan","year":"2009","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.117.079624_bib38","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1038\/nrgastro.2016.3","article-title":"Management of NAFLD: a stage-based approach","volume":"13","author":"Rinella","year":"2016","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1124\/dmd.117.079624_bib39","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1038\/ng.257","article-title":"Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease","volume":"40","author":"Romeo","year":"2008","journal-title":"Nat Genet"},{"key":"10.1124\/dmd.117.079624_bib40","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1136\/gutjnl-2016-312431","article-title":"Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease","volume":"66","author":"Rotman","year":"2017","journal-title":"Gut"},{"key":"10.1124\/dmd.117.079624_bib41","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1016\/S0140-6736(14)61943-7","article-title":"Association between edoxaban dose, concentration, anti-factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial","volume":"385","author":"Ruff","year":"2015","journal-title":"Lancet"},{"key":"10.1124\/dmd.117.079624_bib42","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1007\/s11095-005-9371-5","article-title":"Effects of acid and lactone forms of eight HMG-CoA reductase inhibitors on CYP-mediated metabolism and MDR1-mediated transport","volume":"23","author":"Sakaeda","year":"2006","journal-title":"Pharm Res"},{"key":"10.1124\/dmd.117.079624_bib43","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.cld.2015.10.001","article-title":"Epidemiology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis in the United States and the rest of the world","volume":"20","author":"Sayiner","year":"2016","journal-title":"Clin Liver Dis"},{"key":"10.1124\/dmd.117.079624_bib44","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1002\/cpt.406","article-title":"Pharmacokinetic evaluation of a drug transporter cocktail consisting of digoxin, furosemide, metformin, and rosuvastatin","volume":"100","author":"Stopfer","year":"2016","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.117.079624_bib45","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.1016\/j.xphs.2017.04.044","article-title":"Different involvement of OAT in renal disposition of oral anticoagulants rivaroxaban, dabigatran, and apixaban","volume":"106","author":"Tsuruya","year":"2017","journal-title":"J Pharm Sci"},{"key":"10.1124\/dmd.117.079624_bib46","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1097\/FPC.0000000000000294","article-title":"Impact of ABCB1, ABCG2, and CYP3A5 polymorphisms on plasma trough concentrations of apixaban in Japanese patients with atrial fibrillation","volume":"27","author":"Ueshima","year":"2017","journal-title":"Pharmacogenet Genomics"},{"key":"10.1124\/dmd.117.079624_bib47","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1111\/bcp.12114","article-title":"Effect of extremes of body weight on the pharmacokinetics, pharmacodynamics, safety and tolerability of apixaban in healthy subjects","volume":"76","author":"Upreti","year":"2013","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.117.079624_bib48","doi-asserted-by":"crossref","unstructured":"Wang L, Zhang D, Raghavan N, Yao M, Ma L, Frost CE, Maxwell BD, Chen SY, He K, Goosen TC et al. (2010) In vitro assessment of metabolic drug-drug interaction potential of apixaban through cytochrome P450 phenotyping, inhibition, and induction studies [published correction appears in Drug Metab Dispos (2010) 38:885]. Drug Metab Dispos 38:448\u2013458.","DOI":"10.1124\/dmd.109.029694"},{"key":"10.1124\/dmd.117.079624_bib49","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1124\/jpet.107.125831","article-title":"The contribution of organic anion transporters OAT1 and OAT3 to the renal uptake of rosuvastatin","volume":"322","author":"Windass","year":"2007","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.117.079624_bib50","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1111\/bcpt.12492","article-title":"Relationships between endogenous plasma biomarkers of constitutive cytochrome P450 3A activity and single-time-point oral Midazolam Microdose phenotype in healthy subjects","volume":"118","author":"Woolsey","year":"2016","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"10.1124\/dmd.117.079624_bib51","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1124\/dmd.115.065979","article-title":"CYP3A activity and expression in nonalcoholic fatty liver disease","volume":"43","author":"Woolsey","year":"2015","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.117.079624_bib52","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1124\/dmd.112.050260","article-title":"Characterization of efflux transporters involved in distribution and disposition of apixaban","volume":"41","author":"Zhang","year":"2013","journal-title":"Drug Metab Dispos"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624055259?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624055259?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/dmd.117.079624","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T18:35:35Z","timestamp":1739903735000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955624055259"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":52,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["S0090955624055259"],"URL":"https:\/\/doi.org\/10.1124\/dmd.117.079624","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2018,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Apixaban and Rosuvas\u00ad\u00adtatin Pharmacokinetics in Nonalcoholic Fatty Liver Disease","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/dmd.117.079624","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}